Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STX209 (Arbaclofen) in Subjects With Autism Spectrum Disorders

NCT01706523 is registered in ClinicalTrials.gov with Seaside Therapeutics, Inc. as lead sponsor.

NCT NCT01706523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01706523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of STX209 (Arbaclofen) in Subjects With Autism Spectrum Disorders
Lead sponsor
Seaside Therapeutics, Inc.
Phase
Phase 3
Overall status
Terminated
Start date
November 30, 2011
Completion date
July 31, 2013
Enrollment
165 (estimated)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

autism spectrum disorders